SK Biopharmaceuticals (326030.KS) Earnings Analysis
SK Biopharmaceuticals (326030.KS) next reports earnings on 2026-08-11, consensus EPS 581.55 KRW. Last quarter (2026-05-07) it beat with EPS 1,311.79 KRW vs 481.02 KRW est (+172.7%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E 18.63.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 326030.KS next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | 581.55 KRW |
| Revenue estimate | 232.83B |
326030.KS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 1,311.79 KRW | 481.02 KRW | +172.7% | Beat |
| 2026-02-06 | 1,694.99 KRW | 434.02 KRW | +290.5% | Beat |
| 2025-02-05 | 2,427.63 KRW | 236.84 KRW | +925% | Beat |
| 2024-11-08 | 123 KRW | 184.9 KRW | -33.5% | Miss |
| 2024-08-08 | 359 KRW | 87.9 KRW | +308.4% | Beat |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
326030.KS valuation and analyst view
| Trailing P/E | 18.63 |
|---|---|
| Trailing EPS | 4,559.28 KRW |
| Price / book | 6.54 |
| Dividend yield | 0.00% |
| Market cap | 6014.46B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is SK Biopharmaceuticals (326030.KS)'s next earnings date?
SK Biopharmaceuticals is next scheduled to report on 2026-08-11, with a consensus EPS estimate of 581.55 KRW and revenue estimate of 232.83B.
Did 326030.KS beat earnings last quarter?
In its 2026-05-07 report, 326030.KS posted EPS of 1311.79 KRW versus a 481.02 KRW estimate — a beat of 172.7%.
What is 326030.KS's earnings track record?
Over the last 5 reported quarters with consensus data, 326030.KS beat estimates 4 times (80%).
What is 326030.KS's current P/E ratio and EPS?
326030.KS trades at a trailing P/E of 18.63 on trailing EPS of 4559.28230834586 KRW.
What do analysts rate 326030.KS?
326030.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.